Is tremelimumab/tremelimumab an immunotherapy21?

Tremelimumab/Tremelimumab is an immunotherapy drug that belongs to the anti-CTLA-4 antibody category. It enhances the patient's immune system's ability to attack tumor cells by inhibiting CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), so it is an immune checkpoint inhibitor. This drug can be used to treat certain types of cancer. The basic principle is similar to the already marketed PD-1 and PD-L1 immune drugs, such as pembrolizumab, nivolumab, etc.

Tremelimumab is indicated in combination withdurvalumab for the treatment of adults with unresectable hepatocellular carcinoma and with platinum-based chemotherapy for the first-line treatment of adults with metastatic non-small cell lung cancer who do not have sensitizing epidermal growth factor receptor mutations or anaplastic lymphoma kinase-positive mutations. Compared with chemotherapy alone, tremelimumab combined with durvalumab and chemotherapy can prolong patients' lives. The benefits of tremelimumab outweigh its risks, and the side effects of adding tremelimumab, especially immune-mediated side effects, can be serious, so caution should be used when treating frail or elderly patients.

Tremelimumab/Tremelimumab is a new type of cancer immunotherapy drug. It has not yet been launched in China, so it cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug. It is understood that the US version of temsitumumab original drug sold overseas may cost more than more than 3,000 US dollars per box, and the specification is 300mg/50mL (20mg/mL). The price is still relatively expensive. At present, we are not aware of the production and release of generic drugs of temsitumumab. For specific overseas prices and drug details, please consult Yaode Medical Consultants.